We are pleased to welcome Adrienne Rencic, M.D., Ph.D., as Chief Medical Officer of RAM Pharmaceuticals.

Dr. Rencic is a board-certified dermatologist and physician-scientist with more than two decades of experience spanning academic medicine, complex inflammatory and oncologic disease, biotechnology, and AI-enabled healthcare innovation. She completed her M.D. and Ph.D. at Thomas Jefferson University and her dermatology residency at Johns Hopkins Hospital, where she served as Chief Resident.

As Chief Medical Officer, she will lead the clinical development strategy for RAM’s targeted mucosal delivery platform, with an initial focus on radiation-induced acute oral mucositis in head and neck oncology.

Dr. Rencic states:

“Acute oral mucositis remains one of the most painful and treatment-limiting complications in head and neck radiation oncology. RAM Pharmaceuticals has taken a disciplined, science-driven approach to its targeted delivery platform. Its critical advantage lies in the ability to adhere directly to affected mucosal tissue and dispense medication precisely and consistently where it is needed most.

The prospect of a single modality capable of providing immediate barrier protection and pain relief, together with sustained antiviral and anti-inflammatory activity, represents a meaningful advancement in oral medicine. Radiation therapy in head and neck cancer presents a particularly prevalent, well-defined, and quantifiable clinical pathway toward regulatory evaluation. RAM’s focused strategy in this area reflects a clinically rational first step forward.”

Her appointment marks a significant milestone as we strengthen our clinical leadership and prepare for formal proof-of-concept planning and disciplined advancement of our development program.